Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKesson
Medtronic
Mallinckrodt
Dow
Baxter
Harvard Business School

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

BASAGLAR Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Basaglar patents expire, and when can generic versions of Basaglar launch?

Basaglar is a drug marketed by Eli Lilly And Co and is included in one NDA.

The generic ingredient in BASAGLAR is insulin glargine. There are forty drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the insulin glargine profile page.

Drug patent expirations by year for BASAGLAR
Drug Prices for BASAGLAR

See drug prices for BASAGLAR

Recent Clinical Trials for BASAGLAR

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
LMC Diabetes & Endocrinology Ltd.Phase 4
SanofiPhase 4
Northwestern UniversityPhase 4

See all BASAGLAR clinical trials

Pharmacology for BASAGLAR
Ingredient-typeInsulin
Drug ClassInsulin Analog
Synonyms for BASAGLAR
202757-02-6
21(sup A)-Glycine-30(sup B)a-L-arginine-30(sup B)b-L-arginine insulin (human)
21(sup A)-glycine-30(supp B)a-L-arginine-30(supp B)b-L-arginineinsulin (human)
224055-72-5
2ZM8CX04RZ
690638-50-7
HOE 71GT
HOE 901
Insulin (human), 21(sup A)-glycine-30(sup B)a-L-arginine-30(sup B)b-L-arginine-
Insulin glargine
Insulin glargine [USAN:INN:BAN]
Insulin, glycyl(A21)-arginyl(B31,B32)-
Lantus R
Lantus Solostar
Lusduna Nexvue
LY 2963016
MK-1293
Optisulin
Toujeo
Toujeo Solostar
UNII-2ZM8CX04RZ

US Patents and Regulatory Information for BASAGLAR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eli Lilly And Co BASAGLAR insulin glargine SOLUTION;SUBCUTANEOUS 205692-001 Dec 16, 2015 RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
Boehringer Ingelheim
Baxter
Dow
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.